Evidence map›Paper›PMID 31600053›Full record

ArticleACS nano2019

Cross-linker-Modulated Nanogel Flexibility Correlates with Tunable Targeting to a Sterically Impeded Endothelial Marker.

Jacob Wheatley Myerson, Olivia McPherson, Kelsey G DeFrates, Jenna H Towslee, Oscar A Marcos-Contreras, Vladimir V Shuvaev, Bruce Braender, Russell J Composto, Vladimir R Muzykantov, David M Eckmann

Open access · greenAbstract read
In one paragraph

Article in ACS nano, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Jacob Wheatley MyersonDepartment of Pharmacology, Perelman School of Medicine , University of Pennsylvania , Philadelphia , Pennsylvania 19104 , United States.ORCID 0000-0002-5686-8437
Olivia McPhersonDepartment of Anesthesiology and Critical Care, Perelman School of Medicine , University of Pennsylvania , Philadelphia , Pennsylvania 19104 , United States.
Kelsey G DeFratesDepartment of Anesthesiology and Critical Care, Perelman School of Medicine , University of Pennsylvania , Philadelphia , Pennsylvania 19104 , United States.
Jenna H TowsleeDepartment of Anesthesiology and Critical Care, Perelman School of Medicine , University of Pennsylvania , Philadelphia , Pennsylvania 19104 , United States.
Oscar A Marcos-ContrerasDepartment of Pharmacology, Perelman School of Medicine , University of Pennsylvania , Philadelphia , Pennsylvania 19104 , United States.
Vladimir V ShuvaevDepartment of Pharmacology, Perelman School of Medicine , University of Pennsylvania , Philadelphia , Pennsylvania 19104 , United States.
Bruce BraenderDepartment of Anesthesiology and Critical Care, Perelman School of Medicine , University of Pennsylvania , Philadelphia , Pennsylvania 19104 , United States.
Russell J CompostoDepartment of Bioengineering, School of Engineering and Applied Sciences , University of Pennsylvania , Philadelphia , Pennsylvania 19104 , United States.ORCID 0000-0002-5906-2594
Vladimir R MuzykantovDepartment of Pharmacology, Perelman School of Medicine , University of Pennsylvania , Philadelphia , Pennsylvania 19104 , United States.
David M EckmannDepartment of Anesthesiology and Critical Care, Perelman School of Medicine , University of Pennsylvania , Philadelphia , Pennsylvania 19104 , United States.
University of Pennsylvania · US

Funding

Training in Molecular Therapeutics for Pediatric CardiologyT32HL007915 · NHLBI · CHILDREN'S HOSP OF PHILADELPHIA · PI Robert J Levy, JOSEPH W ROSSANO · 1999 to 2026
$13.4M
Targeted Microcarrier Design and OptimizationR01EB006818 · NIBIB · UNIVERSITY OF PENNSYLVANIA · PI ECKMANN, DAVID M · 2008 to 2016
$3.3M
Targeted nanomedicine for ALI and I/RR01HL125462 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI MUZYKANTOV, VLADIMIR R · 2015 to 2018
$2.3M
Endothelial targeting of antioxidantsR01HL126874 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI MUZYKANTOV, VLADIMIR R · 2016 to 2019
$1.7M
NHLBI NIH HHS R01 HL125462NHLBI NIH HHS R01 HL126874NHLBI NIH HHS T32 HL007915NIBIB NIH HHS R01 EB006818
6 · The paper itself

Abstract

Deformability of injectable nanocarriers impacts rheological behavior, drug loading, and affinity target adhesion. Here, we present atomic force microscopy (AFM) and spectroscopy measurements of nanocarrier Young's moduli, tune the moduli of deformable nanocarriers with cross-linkers, and demonstrate vascular targeting behavior that correlates with Young's modulus. Homobifunctional cross-linkers were introduced into lysozyme-dextran nanogels (NGs). Single particle-scale AFM measurements determined NG moduli varying from ∼50-150 kPa for unmodified NGs or NGs with a short hydrophilic cross-linker (2,2'-(ethylenedioxy)bis(ethylamine), EOD) to ∼350 kPa for NGs modified with a longer hydrophilic cross-linker (4,9-dioxa-1,12-dodecanediamine, DODD) to ∼10 MPa for NGs modified with a longer hydrophobic cross-linker (1,12-diaminododecane, DAD). Cross-linked NGs were conjugated to antibodies for plasmalemma vesicle associated protein (PLVAP), a caveolar endothelial marker that cannot be accessed by rigid particles larger than ∼100 nm. In previous work, 150 nm NGs effectively targeted PLVAP, where rigid particles of similar diameter did not. EOD-modified NGs targeted PLVAP less effectively than unmodified NGs, but more effectively than DODD or DAD modified NGs, which both yielded low levels of targeting, resembling results previously obtained with polystyrene particles. Cross-linked NGs were also conjugated to antibodies against intracellular adhesion molecule-1 (ICAM-1), an endothelial marker accessible to large rigid particles. Cross-linked NGs and unmodified NGs targeted uniformly to ICAM-1. We thus demonstrate cross-linker modification of NGs, AFM determination of NG mechanical properties varying with cross-linker, and tuning of specific sterically constrained vascular targeting behavior in correlation with cross-linker-modified NG mechanical properties.

Indexed as

AnimalsCaveolaeElastic ModulusHumansMembrane ProteinsMicroscopy, Atomic ForceNanogelsNanoparticlesSurface PropertiesMembrane ProteinsNanogelsatomic force microscopycaveolaecross-linkingnanogelsplasmalemma vesicle associated proteintargeted drug delivery

Identifiers

PMID31600053
PMCPMC7393972
OpenAlexW2980262350

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.